A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

OpenAI has inked deals with rival cloud computing partners and spent much of the past two years building out a suite of paid subscription products for businesses, schools and individuals ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has increasingly prioritized weight loss as a key ...

Nektar Therapeutics said on Tuesday its lead drug candidate met the main goal of a mid-stage study testing the drug in eczema patients, sending its shares up by nearly 140%. In the 393-patient global ...

Eagles tight end Dallas Goedert stops by to talk all things Eagles, another year of TEU and his partnership with Amgen.

Last spring, drugmaker Amgen Inc. announced plans to buy  Microsoft Corp.’s Copilot AI assistant for 20,000 employees. It was ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...